MovDisordV3, Main, Exploration, bibRecord, 002B99

Revisiting safety of minocycline as neuroprotection in Huntington's disease

Identifieur interne : 002B99 ( Main/Exploration ); précédent : 002B98; suivant : 002C00

Revisiting safety of minocycline as neuroprotection in Huntington's disease

Auteurs : Norman Reynolds [Niger, États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2007-01-15.

RBID : ISTEX:F04C379147A93E28A0E7BB645F9B074B134F89F3

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Anti-Bacterial Agents (adverse effects), Anti-Bacterial Agents (therapeutic use), Humans, Huntington Disease (drug therapy), Hyperpigmentation (chemically induced), Hyperpigmentation (epidemiology), Middle Aged, Minocycline (adverse effects), Minocycline (therapeutic use), Neuroprotective Agents (adverse effects), Neuroprotective Agents (therapeutic use), Prevalence.
MESH :
- chemical , adverse effects : Anti-Bacterial Agents, Minocycline, Neuroprotective Agents.
- chemical , therapeutic use : Anti-Bacterial Agents, Minocycline, Neuroprotective Agents.
- chemically induced : Hyperpigmentation.
- drug therapy : Huntington Disease.
- epidemiology : Hyperpigmentation.
- Adolescent, Adult, Aged, Humans, Middle Aged, Prevalence.

Url:

https://api.istex.fr/document/F04C379147A93E28A0E7BB645F9B074B134F89F3/fulltext/pdf

DOI: 10.1002/mds.21199

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Revisiting safety of minocycline as neuroprotection in Huntington's disease</title>
<author><name sortKey="Reynolds, Norman" sort="Reynolds, Norman" uniqKey="Reynolds N" first="Norman" last="Reynolds">Norman Reynolds</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F04C379147A93E28A0E7BB645F9B074B134F89F3</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21199</idno>
<idno type="url">https://api.istex.fr/document/F04C379147A93E28A0E7BB645F9B074B134F89F3/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004285</idno>
<idno type="wicri:Area/Istex/Curation">004285</idno>
<idno type="wicri:Area/Istex/Checkpoint">001707</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Reynolds N:revisiting:safety:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17083098</idno>
<idno type="wicri:Area/PubMed/Corpus">002A09</idno>
<idno type="wicri:Area/PubMed/Curation">002A09</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002580</idno>
<idno type="wicri:Area/Ncbi/Merge">001930</idno>
<idno type="wicri:Area/Ncbi/Curation">001930</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001930</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Reynolds N:revisiting:safety:of</idno>
<idno type="wicri:Area/Main/Merge">003B21</idno>
<idno type="wicri:Area/Main/Curation">002B99</idno>
<idno type="wicri:Area/Main/Exploration">002B99</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Revisiting safety of minocycline as neuroprotection in Huntington's disease</title>
<author><name sortKey="Reynolds, Norman" sort="Reynolds, Norman" uniqKey="Reynolds N" first="Norman" last="Reynolds">Norman Reynolds</name>
<affiliation wicri:level="1"><country wicri:rule="url">Niger</country>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin</wicri:regionArea>
<placeName><region type="state">Wisconsin</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-01-15">2007-01-15</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="292">292</biblScope>
<biblScope unit="page" to="292">292</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">F04C379147A93E28A0E7BB645F9B074B134F89F3</idno>
<idno type="DOI">10.1002/mds.21199</idno>
<idno type="ArticleID">MDS21199</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Anti-Bacterial Agents (adverse effects)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Humans</term>
<term>Huntington Disease (drug therapy)</term>
<term>Hyperpigmentation (chemically induced)</term>
<term>Hyperpigmentation (epidemiology)</term>
<term>Middle Aged</term>
<term>Minocycline (adverse effects)</term>
<term>Minocycline (therapeutic use)</term>
<term>Neuroprotective Agents (adverse effects)</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Prevalence</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Minocycline</term>
<term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term>
<term>Minocycline</term>
<term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hyperpigmentation</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Hyperpigmentation</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Prevalence</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>Niger</li>
<li>États-Unis</li>
</country>
<region><li>Wisconsin</li>
</region>
</list>
<tree><country name="Niger"><noRegion><name sortKey="Reynolds, Norman" sort="Reynolds, Norman" uniqKey="Reynolds N" first="Norman" last="Reynolds">Norman Reynolds</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Wisconsin"><name sortKey="Reynolds, Norman" sort="Reynolds, Norman" uniqKey="Reynolds N" first="Norman" last="Reynolds">Norman Reynolds</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B99 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B99 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F04C379147A93E28A0E7BB645F9B074B134F89F3
   |texte=   Revisiting safety of minocycline as neuroprotection in Huntington's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Revisiting safety of minocycline as neuroprotection in Huntington's disease

Revisiting safety of minocycline as neuroprotection in Huntington's disease

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.